Huperzine A: An Overview

Huperzine A, primarily sourced from plants of the Huperziceae family, is a recognized acetylcholinesterase inhibitor. This means it acts to hinder the enzyme responsible for breaking down acetylcholine, leading to elevated acetylcholine levels.

Acetylcholine is a crucial neurotransmitter associated with learning and muscle contraction. Elevating acetylcholine levels is a prevalent strategy both in academic performance enhancement and weightlifting. Research involving animal toxicity studies and human trials suggest that Huperzine A is generally safe at commonly supplemented doses. Optimal acetylcholine levels have several benefits, including:

• Neurodegeneration prevention,
• Memory enhancement,
• Oxidative balance maintenance.³

What Is Huperzine A?

Huperzine A (HupA) is a natural inhibitor of acetylcholinesterase (AChE) derived from the traditional Chinese medicinal plant, Huperzia Serrata. For centuries, H. serrata has been used in China to address various medical conditions such as swelling, rheumatism, schizophrenia, and fever. Notably, HupA is approved for Alzheimer’s treatment in China and is available as a dietary supplement in the US. An increasing number of studies indicate its potential in treating cognitive impairments across different species, including humans.
Huperzine A, commonly referred to as HupA, is associated with an enhancement in cognitive performance, daily activities, and overall clinical assessment among individuals with Alzheimer’s disease (AD). These findings have been substantiated by a comprehensive review and meta-analysis of randomized clinical trials⁷.

Mechanism of Action

Huperzine A is a distinct water-soluble alkaloid that has the capability to readily penetrate the blood-brain barrier, dispersing throughout the brain in a short span. After ingestion, it can be detected in the bloodstream within just 5-10 minutes and typically peaks around an hour. Remarkably, its half-life is roughly 10 hours, with most of it being excreted through urine within 24 hours¹⁰.

A significant attribute of Huperzine A is its ability to inhibit the G4 isoform of acetylcholinesterase in the brain, an enzyme known for degrading acetylcholine. By doing so, Huperzine A effectively boosts acetylcholine levels, which play a pivotal role in various cognitive functions and are essential for forming new memories. Furthermore, higher acetylcholine levels enhance neural signaling and improve cortical circuit response times, while simultaneously decreasing excitatory feedback that might impede memory retrieval¹¹.

Furthermore, Huperzine A is recognized for its potent antioxidant properties. It is not only effective in neutralizing oxidative stress but also, in certain situations, can prevent and even reverse free radical-induced damage in the brain. This antioxidative capability is believed to contribute significantly to Huperzine A’s potential as a supplementary treatment for Alzheimer’s disease and other related neurological conditions.

Another mechanism through which Huperzine A promotes neuroprotection is by guarding the brain against glutamate toxicity. It achieves this by restraining specific glutamate receptors, which in turn prevents excessive activation of neurons. This regulatory action aids in maintaining glutamate levels, shielding the brain from persistent glutamate toxicity—a factor implicated in dementia and other age-associated neural anomalies.

Benefits of Huperzine A Supplementation

Neuroprotectant

Huperzine A serves as a notable neuroprotectant, providing shielding against oxidative damage — a primary factor associated with the aging process. Oxidative damage has been implicated in many age-related conditions, and it is believed to substantially contribute to the progression of Alzheimer’s disease and other neurodegenerative disorders.¹
Oxidative damage arises from the splitting of oxygen molecules into individual atoms, a regular physiological occurrence. Typically, atoms are surrounded by paired electrons that orbit in layers. However, as aging occurs, this process becomes less efficient, leading to the formation of atoms lacking a full set of electrons. These incomplete atoms, known as free radicals, become unstable and scavenge nearby cells to achieve electron stability.

When free radicals interact with neighboring cells, they initiate a chain of detrimental chemical reactions, ultimately destabilizing the cells from which they extract electrons. This harmful activity can be neutralized by antioxidants — molecules capable of donating an electron to a free radical without becoming destabilized themselves. If antioxidant activity matches or surpasses free radical activity, it results in a protective effect. Conversely, an excess of free radical activity leads to oxidative stress, which can cause extensive damage to lipids, proteins, and DNA.²³

Memory Enhancer

Huperzine A functions as a cognitive booster by elevating acetylcholine levels in the brain. Acetylcholine is a vital neurotransmitter that plays a pivotal role in several cognitive functions.⁴ Huperzine A has been shown to effectively inhibit acetylcholinesterase, the enzyme responsible for breaking down acetylcholine. As a result, there’s an enhancement in acetylcholine concentration in the brain, bolstering overall cognition and specifically augmenting memory functions.

While Huperzine A plays a pivotal role in Alzheimer’s disease treatment⁵, studies also suggest its potential to enhance memory and learning in healthy young individuals.⁶

Glutamate Toxicity Protection

Glutamate is an essential excitatory neurotransmitter that facilitates nerve cell communication. It’s vital for learning and memory at regular concentrations. Yet, at elevated levels, glutamate can become toxic, leading to cell damage or even death. Symptoms of chronic glutamate toxicity include anxiety, restlessness, heightened pain sensitivity, and reduced concentration abilities. This toxicity is of particular concern for the elderly, as age seems to increase receptor sensitivity, making neurons more susceptible to glutamate-induced harm.⁷

Huperzine A acts as a glutamate receptor antagonist, countering the overactivation of neurons by glutamate.⁸ This property helps balance glutamate levels, providing a therapeutic avenue for neurodegenerative conditions.

Neurogenesis

Huperzine A stimulates the ERK pathway, encouraging the growth of hippocampal neural stem cells (NSCs). In vivo studies, using Huperzine A infusions at 0.2 mg/kg for four weeks, have verified this neurogenesis, revealing about a 25% rise in BrdU-stained cells in both young and adult mice.²

Recommended Dosage

Although there isn’t a universally agreed-upon dosage for Huperzine A, research trials have safely administered the following doses: 50–200 mcg twice daily for Alzheimer’s treatment, and 100 mcg twice daily for memory enhancement.²⁰

The supplement can be taken at any time, with or without food. Due to its lengthy half-life, it’s recommended to cycle the supplement — typically, 2–4 weeks of use followed by a break. However, the ideal cycle length remains unspecified.²⁰

1. Qian, Zhong Ming, and Xun Shen. 2001. “Brain Iron Transport and Neurodegeneration.” Trends in Molecular Medicine 7 (3): 103–8. https://doi.org/10.1016/s1471-4914(00)01910-9.

2. Ratia, M., L. Giménez-Llort, P. Camps, D. Muñoz-Torrero, B. Pérez, M.V. Clos, and A. Badia. 2013. “Huprine X and Huperzine a Improve Cognition and Regulate Some Neurochemical Processes Related with Alzheimer’S Disease in Triple Transgenic Mice (3xTg-AD).” Neurodegenerative Diseases 11 (3): 129–40. https://doi.org/10.1159/000336427.

3. Skolnick, Andrew A. 1997. “Old Chinese Herbal Medicine Used for Fever Yields Possible New Alzheimer Disease Therapy.” JAMA: The Journal of the American Medical Association 277 (10): 776. https://doi.org/10.1001/jama.1997.03540340010004.

4. Ma, Xiaoqiang, Changheng Tan, Dayuan Zhu, David R. Gang, and Peigen Xiao. 2007. “Huperzine a from Huperzia Species—an Ethnopharmacolgical Review.” Journal of Ethnopharmacology 113 (1): 15–34. https://doi.org/10.1016/j.jep.2007.05.030.

5. Erdogan Orhan, I., G. Orhan, and E. Gurkas. 2011. “An Overview on Natural Cholinesterase Inhibitors – A Multi-Targeted Drug Class – and Their Mass Production.” Mini-Reviews in Medicinal Chemistry 11 (10): 836–42. https://doi.org/10.2174/138955711796575434.

6. Howes, Melanie-Jayne R., and Elaine Perry. 2011. “The Role of Phytochemicals in the Treatment and Prevention of Dementia.” Drugs & Aging 28 (6): 439–68. https://doi.org/10.2165/11591310-000000000-00000.

7. Xing, Shu-huai, Chun-xiao Zhu, Rui Zhang, and Li An. 2014. “Huperzine a in the Treatment of Alzheimer’s Disease and Vascular Dementia: A Meta-Analysis.” Evidence-Based Complementary and Alternative Medicine 2014: 1–10. https://doi.org/10.1155/2014/363985.

8. Yang, Ling, Chun-yan Ye, Xiao-tian Huang, Xi-can Tang, and Hai-yan Zhang. 2012. “Decreased Accumulation of Subcellular Amyloid-β with Improved Mitochondrial Function Mediates the Neuroprotective Effect of Huperzine A.” Journal of Alzheimer’s Disease 31 (1): 131–42. https://doi.org/10.3233/jad-2012-120274.

9. Li, Y. X., R. Q. Zhang, C. R. Li, and X. H. Jiang. 2007. “Pharmacokinetics of Huperzine a Following Oral Administration to Human Volunteers.” European Journal of Drug Metabolism and Pharmacokinetics 32 (4): 183–87. https://doi.org/10.1007/bf03191002.

10. Zhao, Qin, and Xi Can Tang. 2002. “Effects of Huperzine a on Acetylcholinesterase Isoforms in Vitro: Comparison with Tacrine, Donepezil, Rivastigmine and Physostigmine.” European Journal of Pharmacology 455 (2–3): 101–7. https://doi.org/10.1016/s0014-2999(02)02589-x.

11. Beatty, Stephen, Hui-Hiang Koh, M Phil, David Henson, and Michael Boulton. 2000. “The Role of Oxidative Stress in the Pathogenesis of Age-Related Macular Degeneration.” Survey of Ophthalmology 45 (2): 115–34. https://doi.org/10.1016/s0039-6257(00)00140-5.

12. Pohanka, Miroslav, Martina Hrabinova, Filip Zemek, Lucie Drtinova, Hana Bandouchova, and Jiri Pikula. 2011. “Huperzine Induces Alteration in Oxidative Balance and Antioxidants in a Guinea Pig Model.” Neuro Endocrinology Letters 32 (Suppl 1): 95–100.

13. Ha, Giang T., Ryan K. Wong, and Yan Zhang. 2011. “Huperzine a as Potential Treatment of Alzheimer’s Disease: An Assessment on Chemistry, Pharmacology, and Clinical Studies.” Chemistry & Biodiversity 8 (7): 1189–1204. https://doi.org/10.1002/cbdv.201000269.

14. Little, John T, Sally Walsh, and Paul S Aisen. 2008. “An Update on Huperzine a as a Treatment for Alzheimer’s Disease.” Expert Opinion on Investigational Drugs 17 (2): 209–15. https://doi.org/10.1517/13543784.17.2.209.

15. Yang, Guoyan, Yuyi Wang, Jinzhou Tian, and Jian-Ping Liu. 2013. “Huperzine a for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.” Edited by Roberta W. Scherer. PLoS ONE 8 (9): e74916. https://doi.org/10.1371/journal.pone.0074916.

16. Sun, Q. Q., S. S. Xu, J. L. Pan, H. M. Guo, and W. Q. Cao. 1999. “Huperzine-A Capsules Enhance Memory and Learning Performance in 34 Pairs of Matched Adolescent Students.” Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica 20 (7): 601–3.

17. Lewerenz, Jan, and Pamela Maher. 2015. “Chronic Glutamate Toxicity in Neurodegenerative Diseases—What Is the Evidence?” Frontiers in Neuroscience 9 (December). https://doi.org/10.3389/fnins.2015.00469.

18. Zhang, J.-M, and G.-Y Hu. 2001. “Huperzine A, a Nootropic Alkaloid, Inhibits N-Methyl-D-Aspartate-Induced Current in Rat Dissociated Hippocampal Neurons.” Neuroscience 105 (3): 663–69. https://doi.org/10.1016/s0306-4522(01)00206-8.

19. Ma, Tuo, Kai Gong, Yufang Yan, Lihai Zhang, Peifu Tang, Xiufang Zhang, and Yandao Gong. 2013. “Huperzine a Promotes Hippocampal Neurogenesis in Vitro and in Vivo.” Brain Research 1506 (April): 35–43. https://doi.org/10.1016/j.brainres.2013.02.026.

20. Kozikowski, Alan P., and Werner Tückmantel. 1999. “Chemistry, Pharmacology, and Clinical Efficacy of the Chinese Nootropic Agent Huperzine A.” Accounts of Chemical Research 32 (8): 641–50. https://doi.org/10.1021/ar9800892.